- A pioneering cancer vaccine, developed by the University of Oxford and Moderna, is scheduled to undergo trials this summer.
- The jab targets patients with Lynch syndrome, who are at high risk of developing bowel and ovarian cancer.
- The study aims to investigate the vaccine’s ability to train the immune system to identify and eliminate pre-cancerous cells in people with Lynch syndrome, aiming to prevent cancer from developing.
- The initiative represents Moderna's first venture into cancer prevention with its mRNA technology, while Oxford experts believe the approach could be adapted for other cancer types in the future.
- The initial Intercept-Lynch trial will assess immune responses, optimal dosage, and safety, with a second phase expected to commence in 2027.
IN FULL
